TD Asset Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $91.4M | Buy |
168,649
+64,061
| +61% | +$36.1M | 0.08% | 201 |
|
|
2026
Q1 | $62M | Sell |
104,588
-8,547
| -8% | -$4.26M | 0.05% | 271 |
|
|
2025
Q4 | $55.1M | Sell |
113,135
-25,724
| -19% | -$12M | 0.04% | 300 |
|
|
2025
Q3 | $58.2M | Buy |
138,859
+6,581
| +5% | +$2.21M | 0.05% | 289 |
|
|
2025
Q2 | $38M | Sell |
132,278
-15,633
| -11% | -$4.67M | 0.03% | 380 |
|
|
2025
Q1 | $45.6M | Sell |
147,911
-2,543
| -2% | -$871K | 0.04% | 335 |
|
|
2024
Q4 | $53.1M | Buy |
150,454
+8,088
| +6% | +$2.97M | 0.05% | 304 |
|
|
2024
Q3 | $51M | Buy |
142,366
+28,584
| +25% | +$9.66M | 0.05% | 307 |
|
|
2024
Q2 | $36.2M | Buy |
113,782
+32,245
| +40% | +$8.53M | 0.03% | 348 |
|
|
2024
Q1 | $18.7M | Sell |
81,537
-1,414
| -2% | -$319K | 0.02% | 507 |
|
|
2023
Q4 | $18.2M | Buy |
82,951
+75,839
| +1,066% | +$17.5M | 0.02% | 501 |
|
|
2023
Q3 | $1.61M | Buy |
7,112
+3,750
| +112% | +$864K | ﹤0.01% | 1020 |
|
|
2023
Q2 | $742K | Buy |
3,362
+49
| +1% | +$10.9K | ﹤0.01% | 1190 |
|
|
2023
Q1 | $742K | Buy |
+3,313
| New | +$817K | ﹤0.01% | 1193 |
|
|
2022
Q4 | – | Sell |
-52,611
| Closed | -$10.9M | – | 1497 |
|
|
2022
Q3 | $10.9M | Sell |
52,611
-4,628
| -8% | -$1.03M | 0.01% | 561 |
|
|
2022
Q2 | $13.5M | Buy |
57,239
+16,498
| +40% | +$3.35M | 0.02% | 526 |
|
|
2022
Q1 | $7.31M | Buy |
40,741
+2
| +0% | +$381 | 0.01% | 733 |
|
|
2021
Q4 | $8.8M | Buy |
+40,739
| New | +$8M | 0.01% | 711 |
|
|
2021
Q2 | – | Sell |
-19,637
| Closed | -$3.29M | – | 1572 |
|
|
2021
Q1 | $3.29M | Buy |
19,637
+8,937
| +84% | +$1.49M | ﹤0.01% | 947 |
|
|
2020
Q4 | $1.62M | Buy |
+10,700
| New | +$1.4M | ﹤0.01% | 1083 |
|
|
2020
Q2 | – | Sell |
-11,800
| Closed | -$1.12M | – | 1420 |
|
|
2020
Q1 | $1.12M | Buy |
+11,800
| New | +$1.12M | ﹤0.01% | 967 |
|
|
2017
Q2 | – | Sell |
-33,178
| Closed | -$4.49M | – | 1371 |
|
|
2017
Q1 | $4.49M | Sell |
33,178
-40
| -0.1% | -$6.06K | 0.01% | 711 |
|
|
2016
Q4 | $4.76M | Buy |
33,218
+30,781
| +1,263% | +$3.93M | 0.01% | 691 |
|
|
2016
Q3 | $288K | Sell |
2,437
-713
| -23% | -$85.7K | ﹤0.01% | 1316 |
|
|
2016
Q2 | $334K | Buy |
3,150
+350
| +13% | +$39K | ﹤0.01% | 1235 |
|
|
2016
Q1 | $312K | Buy |
2,800
+100
| +4% | +$12.7K | ﹤0.01% | 1220 |
|
|
2015
Q4 | $423K | Sell |
2,700
-23,300
| -90% | -$3.39M | ﹤0.01% | 1146 |
|
|
2015
Q3 | $3.41M | Sell |
26,000
-4,000
| -13% | -$642K | 0.01% | 730 |
|
|
2015
Q2 | $5.22M | Buy |
30,000
+1,100
| +4% | +$198K | 0.01% | 657 |
|
|
2015
Q1 | $4.98M | Buy |
28,900
+3,000
| +12% | +$457K | 0.01% | 665 |
|
|
2014
Q4 | $3.35M | Buy |
25,900
+2,900
| +13% | +$374K | 0.01% | 760 |
|
|
2014
Q3 | $2.96M | Sell |
23,000
-1,500
| -6% | -$155K | 0.01% | 760 |
|
|
2014
Q2 | $2.17M | Sell |
24,500
-1,300
| -5% | -$125K | ﹤0.01% | 819 |
|
|
2014
Q1 | $2.43M | Buy |
25,800
+12,300
| +91% | +$1.26M | ﹤0.01% | 799 |
|
|
2013
Q4 | $1.53M | Buy |
13,500
+6,800
| +101% | +$613K | ﹤0.01% | 840 |
|
|
2013
Q3 | $528K | Buy |
6,700
+400
| +6% | +$29.2K | ﹤0.01% | 964 |
|
|
2013
Q2 | $415K | Buy |
+6,300
| New | +$406K | ﹤0.01% | 968 |
|
Other funds holding UTHR
VPM
VCM
TD Asset Management's UTHR Position: Q2 2026 in Review
TD Asset Management increased its United Therapeutics (UTHR) stake by 61% in Q2 2026, buying an estimated $36.1M and bringing the position to 168,649 shares worth $91.4M. The position accounts for 0.08% of the portfolio, ranked #201.
TD Asset Management first reported a position in UTHR in Q2 2013 and has held it in 37 quarters since. 647 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- TD Asset Management held 168,649 shares of United Therapeutics worth $91.4M as of Q2 2026.
- TD Asset Management bought 64,061 United Therapeutics shares in Q2 2026, an estimated $36.1M.
- United Therapeutics made up 0.08% of TD Asset Management's portfolio in Q2 2026, its #201 holding.
- TD Asset Management first reported a position in United Therapeutics in Q2 2013 and has held it in 37 quarters since.
- 647 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.